"Pion, M." . "HIV 1; inhibitors of reverse transcriptase"@en . "80" . "R5 varianty HIV 1 p\u0159ednostn\u011B infikuj\u00ED T bu\u0148ky typu CD62L- CD4+ a jsou potenci\u00E1ln\u011B rezistentn\u00ED v\u016F\u010Di nukleosidov\u00FDm inhibitor\u016Fm reverzn\u00ED transkript\u00E1zy"@cs . . "Hirsch, I." . . "2"^^ . "We investigated the effect of the activation status of CD4+ T cells on the predominance of R5 and X4 HIV-1 variants in different subsets of CD4+ T cells in ex vivo-infected human lymphoid tissues and PBMCs. In these cell systems, we examined the sensitivity of HIV replication to reverse transcriptase inhibitors. We demonstrate that R5 HIV-1 variants preferentially produced productive infection in slowly dividing HLA-DR- CD62L- CD4+ T cells. In contrast, X4 HIV-1 variants preferentially produced productive infection in activated HLA-DR+ CD62L+ CD4+ T cells. The abilities of the nucleoside reverse transcriptase inhibitors to stop HIV-1 replication were 20 times greater in activated T cells than in slowly dividing HLA-DR- CD62L- CD4+ T cells. Thes result correlated with higher levels of thymidine kinase mRNA in activated than in slowly dividing HLA-DR- CD62L- CD4+ T cells. The non-nucleoside reverse transcriptase inhibitor was equally efficient in both cell substets."@en . "R5 varianty HIV 1 p\u0159ednostn\u011B infikuj\u00ED T bu\u0148ky typu CD62L- CD4+ a jsou potenci\u00E1ln\u011B rezistentn\u00ED v\u016F\u010Di nukleosidov\u00FDm inhibitor\u016Fm reverzn\u00ED transkript\u00E1zy"@cs . "Fernandez, M. A." . "Biancotto, A." . . . "R5 variants of human immunodeficiency virus type 1 preferentially infect CD62L- CD4+ T cells and are potentially resistant to nucleoside reverse transcriptase inhibitors"@en . "498326" . "0022-538X" . . . "We investigated the effect of the activation status of CD4+ T cells on the predominance of R5 and X4 HIV-1 variants in different subsets of CD4+ T cells in ex vivo-infected human lymphoid tissues and PBMCs. In these cell systems, we examined the sensitivity of HIV replication to reverse transcriptase inhibitors. We demonstrate that R5 HIV-1 variants preferentially produced productive infection in slowly dividing HLA-DR- CD62L- CD4+ T cells. In contrast, X4 HIV-1 variants preferentially produced productive infection in activated HLA-DR+ CD62L+ CD4+ T cells. The abilities of the nucleoside reverse transcriptase inhibitors to stop HIV-1 replication were 20 times greater in activated T cells than in slowly dividing HLA-DR- CD62L- CD4+ T cells. Thes result correlated with higher levels of thymidine kinase mRNA in activated than in slowly dividing HLA-DR- CD62L- CD4+ T cells. The non-nucleoside reverse transcriptase inhibitor was equally efficient in both cell substets." . . . . "8"^^ . "Gondois-Rey, F." . "Z(AV0Z50520514)" . "R5 variants of human immunodeficiency virus type 1 preferentially infect CD62L- CD4+ T cells and are potentially resistant to nucleoside reverse transcriptase inhibitors" . . "Trejbalov\u00E1, Kate\u0159ina" . . "R5 variants of human immunodeficiency virus type 1 preferentially infect CD62L- CD4+ T cells and are potentially resistant to nucleoside reverse transcriptase inhibitors"@en . . "V ex-vivo infikovan\u00E9 lidsk\u00E9 lymfoidn\u00ED tk\u00E1ni a v PBMC jsme sledovali vliv aktivace CD4+ T bun\u011Bk na p\u0159eva\u017Euj\u00EDc\u00ED v\u00FDskyt R5 nebo X4 variant HIV-1 v r\u016Fzn\u00FDch subpopulac\u00EDch CD4+ T bun\u011Bk. V t\u011Bchto syst\u00E9mech jsme d\u00E1le sledovali citlivost replikace HIV k inhibitor\u016Fm reverzn\u00ED transkript\u00E1zy. Prok\u00E1zali jsme, \u017Ee R5 varianty HIV-1 p\u0159ednostn\u011B vyvol\u00E1vaj\u00ED produktivn\u00ED infekci v pomalu se d\u011Bl\u00EDc\u00EDch HLA-DR- CD62L- CD4+ T bu\u0148k\u00E1ch. Naproti tomu X4 varianty HIV-1 vyvol\u00E1vaj\u00ED produktivn\u00ED infekci p\u0159ednostn\u011B v aktivovan\u00FDch HLA-DR+ CD62L+ CD4+ T bu\u0148k\u00E1ch. Schopnost nukleozidov\u00FDch inhibitor\u016F reverzn\u00ED transkript\u00E1zy inhibovat HIV-1 replikaci byla 20kr\u00E1t vy\u0161\u0161\u00ED v aktivovan\u00FDch T bu\u0148k\u00E1ch ne\u017E v pomalu se d\u011Bl\u00EDc\u00EDch HLA-DR- CD62L- CD4+ T bu\u0148k\u00E1ch. Hladina thymidin kin\u00E1zov\u00E9 mRNA korelovala s intenzitou bun\u011B\u010Dn\u00E9ho r\u016Fstu a byla vy\u0161\u0161\u00ED v bu\u0148k\u00E1ch citliv\u00FDch na nukleozidov\u00E9 inhibitory reverzn\u00ED transkript\u00E1zy. Nenukleozidov\u00FD inhibitor reverzn\u00ED transkript\u00E1zy byl stejn\u011B \u00FA\u010Dinn\u00FD v obou typech bun\u011Bk."@cs . "Bettendroffer, L." . "854;865" . "Journal of Virology" . . "US - Spojen\u00E9 st\u00E1ty americk\u00E9" . . . "RIV/68378050:_____/06:00048943" . "R5 variants of human immunodeficiency virus type 1 preferentially infect CD62L- CD4+ T cells and are potentially resistant to nucleoside reverse transcriptase inhibitors" . "RIV/68378050:_____/06:00048943!RIV07-AV0-68378050" . "12"^^ . "2" . "[CEA24273FC12]" . "Bla\u017Ekov\u00E1, Jana" .